Latest 2010

Geron Initiates Clinical Trial of Human Embryonic Stem Cell-based Therapy in Patients with Spinal Cord Injury

Geron Initiates Clinical Trial of Human Embryonic Stem Cell-based Therapy in Patients with Spinal Cord Injury

October 11, 2010

Geron Corporation (Nasdaq: GERN) today announced the enrollment of the first patient in the company’s clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with “complete” American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

Read more

OTHER PROJECTS

See how else UKSCF is helping stem cell research.

Read More
 OTHER PROJECTS

SUPPORT US

Your donations and fundraising help to advance the most promising research projects that have the greatest potential to deliver patient benefits.

Read more
SUPPORT US